Hikma Prepares For Push Into MENA Oncology Biologics Market
Having enjoyed some success in the Middle East and North Africa region with its Remsima infliximab biosimilar for autoimmune disorders, Hikma is lining up launches of both rituximab and trastuzumab into the region’s oncology arena.
You may also be interested in...
To secure long-term growth, Hikma CEO Siggi Olafsson is seeking to add a fourth strategic pillar to its global generic Injectables, US non-injectable Generics and Middle East and North Africa Branded business segments.
Extra capacity coming online at a high-containment facility in Portugal is opening up opportunities for Hikma to expand its presence in Europe’s injectables market.
Hikma says it has considerably broadened access to infliximab in Morocco by introducing its Remsima biosimilar early last year. The Jordanian firm claims to have helped increase the size of the local market by about 50% to 11,000 vials per year whilst raising Remsima’s market share to more than 75%. “This example demonstrates how we grow our business and we are not limited to taking market share from the originator,” commented Hikma’s chief executive officer Siggi Olafsson.